AptarGroup, Inc. (ATR) AI Stock Analysis

AptarGroup, Inc. specializes in designing and manufacturing drug delivery, consumer product dispensing, and active material science solutions and services. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. In the Pharma segment, it supplies components including pumps for nasal allergy treatments, metered dose inhaler valves for asthma and chronic obstructive pulmonary diseases, and elastomers for injectable primary packaging. The Beauty + Home segment provides pumps, closures, aerosol valves, accessories, and decorative components for personal care, home care, and beauty products. The Food + Beverage segment provides dispensing and non-dispensing closures and elastomeric flow control solutions.

AptarGroup's revenue expanded at a 5-year CAGR of 5.2% from FY2020 to FY2025. Annual revenue grew from $3.23B in FY2021 to $3.78B in FY2025, with revenue growth of 5.4% in FY2025. Operating margin rose from 10.8% in FY2021 to 13.6% in FY2025, while gross margin stood at 29.6% in FY2025 compared to 37.8% in FY2024. Net income reached $392.8M in FY2025 with EPS of $5.73. Over the trailing twelve months, revenue reached $3.93B with a net profit margin of 9.2%. For the latest quarter ending June 30, 2026, quarterly revenue grew 6.3% year-over-year, while quarterly earnings declined 18.6%.

As of June 30, 2026, AptarGroup held $197.3M in cash and short-term investments against total debt of $1.43B, resulting in net debt of $1.23B. Total assets stood at $5.13B and shareholders' equity was $2.63B, yielding a debt-to-equity ratio of 0.54 and a current ratio of 1.61. In FY2025, the company generated operating cash flow of $570.0M and directed $270.4M to capital expenditures. Cash allocation included $365.0M for share buybacks and $120.8M for dividends paid, contributing to a 5-year share count reduction of 4.3%.

AptarGroup trades at a trailing P/E of 22.5x and a forward P/E of 19.8x. Compared to the median of its US-listed Healthcare peers, its trailing P/E of 22.5x sits below the peer median of 24.6x, while its forward P/E is above the peer median of 17.3x. Its EV-to-EBITDA multiple is 11.1x versus the peer median of 12.0x, and its price-to-sales multiple is 2.0x compared to the peer median of 4.1x. Over the past year, the stock returned -2.1% against a 16.8% gain for the S&P 500 (SPY), and over five years returned 3.7% compared to 83.0% for the index.

AptarGroup pays a forward annual dividend of $1.92 per share, representing a dividend yield of 1.54% and a payout ratio of 35.0%. The dividend is distributed quarterly and has been paid for 34 consecutive years. Over the last five years, the dividend grew at an annualized rate of 4.9%. The most recent ex-dividend date was July 30, 2026.

Wall Street analysts maintain 6 Strong Buy, 2 Buy, and 2 Hold ratings on AptarGroup, with no Sell or Strong Sell ratings. The mean price target is $161.44, representing a 29.7% premium over the last close of $124.51. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $3.98B and EPS of $5.50, an EPS decline of 4.1%. For the following year, 10 analysts forecast revenue of $4.13B and EPS of $6.18. AptarGroup beat EPS estimates in all 4 of its last four quarters, with its next earnings date scheduled for October 29, 2026.

This page is an AI-written research summary of AptarGroup, Inc. (ATR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ATR income statement, ATR balance sheet, ATR key metrics, ATR analyst forecast, ATR chart. See the ATR stock overview for the latest quote and news.